beta
Trial Radar AI
Clinical Trial NCT06629090 for Magnetic Resonance Imaging, Cerebrovascular Circulation is not yet recruiting. See the Trial Radar Card View and AI discovery tools for all the details. Or ask anything here.
One trial matched filter criteria
Card View
Back to Search

Brain Blood Vessel Responses to Changes in Blood Flow: Younger Cohort

Not yet recruiting
Clinical Trial NCT06629090 is designed to study Basic Science for Magnetic Resonance Imaging, Cerebrovascular Circulation. This Phase 2 interventional trial is not yet recruiting. Enrollment is planned to begin on January 1, 2026 until the trial accrues 36 participants. Led by University of Wisconsin, Madison, this trial is expected to complete by December 1, 2026. The latest data from ClinicalTrials.gov was last updated on December 2, 2025.
Brief Summary
Brain blood flow will be measured during a simulated postural change test and while breathing increased levels of carbon dioxide using magnetic resonance imaging.
Detailed Description
Global cerebral blood flow (CBF) decreases with advancing age; however, some adults have accelerated declines in CBF, placing them at a greater risk of cognitive impairment. However, there is a lack of human studies that investigate the cause or consequence of altered blood flow regulation in the brain. This study will systematically address this gap in knowledge by examining cerebrovascular control in adults during acute physiological challenges (simulated postural change test and breathing increased carbon dioxide) that stimulate a change in CBF.
Official Title

Cerebrovascular Responses to Acute Hypoperfusion

Conditions
Magnetic Resonance ImagingCerebrovascular Circulation
Other Study IDs
  • 2024-0377: Younger Cohort
  • A176000 (Other Identifier) (UW- Madison)
  • EDUC/KINESIOLOGY (Other Identifier) (UW- Madison)
  • Protocol Version 7/29/2025 (Other Identifier) (UW- Madison)
NCT ID Number
NCT06629090
Start Date (Actual)
2026-01
Last Update Posted
2025-12-02
Completion Date (Estimated)
2026-12
Enrollment (Estimated)
36
Study Type
Interventional
PHASE
Phase 2
Status
Not yet recruiting
Keywords
Magnetic Resonance Imaging
Brain Blood Flow
Lower Body Negative Pressure
Carbon Dioxide
Primary Purpose
Basic Science
Design Allocation
N/A
Interventional Model
Single Group
Masking
None (Open Label)
Arms / Interventions
Participant Group/ArmIntervention/Treatment
ExperimentalYoung Adults
Young Adults between 20-40 years of age.
MRI
Participants will undergo an MRI scan while performing breathing and simulated postural change tasks.
Prazosin
A dose of prazosin will be administered based on body weight
Placebo
Oral placebo
Primary Outcome Measures
Outcome MeasureMeasure DescriptionTime Frame
Change in blood velocity
The change in blood velocity during breathing and simulated postural change tasks will be measured with MRI
Two study visits, up to 240 minutes
Change in blood flow
The change in intracranial blood flow during breathing and simulated postural change tasks will be measured with MRI
Two study visits, up to 240 minutes
Eligibility Criteria

Eligible Ages
Adult
Minimum Age
20 Years
Eligible Sexes
All
Accepts Healthy Volunteers
Yes
  • Between the ages of 20-40 years
  • Have a BMI ≤34.5 kg/m2
  • are less than 72 in (182.88 cm) height
  • Nonsmoker

  • Diagnosis of Mild Cognitive Impairment (MCI) or Alzheimer's disease (AD)
  • History or evidence of hepatic disease, hematological disease, or peripheral vascular disease; severe kidney injury requiring hemodialysis
  • History of cardiovascular disease including: severe congestive heart failure, coronary artery disease, ischemic heart disease (stents, coronary artery bypass grafts) and tachycardia
  • Uncontrolled hypertension
  • History of clinically significant ischemic or hemorrhagic stroke, or significant cerebrovascular disease
  • Severe untreated obstructive sleep apnea
  • History of diabetes with HbA1c greater than 9.5 percent
  • Major neurologic disorders other than dementia (e.g., MS, ALS, brain surgery, etc.)
  • Current or recent (less than1 year) major psychiatric condition (Axis I) or addictive disorders
  • Significant surgical history
  • Other significant medical conditions at investigators' discretion
  • Contraindications to MRI
  • Prescribed medications that interfere with prazosin
  • Lactose allergy
  • lower body will not fit in lower body negative pressure (LBNP) chamber (regardless of overall height and BMI)
University of Wisconsin, Madison logoUniversity of Wisconsin, Madison247 active trials to explore
Study Central Contact
Contact: Anna Howery, 608-262-9572, [email protected]
1 Study Locations in 1 Countries

Wisconsin

University of Wisconsin, Madison, Wisconsin, 53705, United States
Anna J Howery, MS, Contact, 608-262-9572, [email protected]
Jill N Barnes, PhD, Principal Investigator